This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
Mayo Clinic Identifier:
First received: May 14, 2008
Last updated: November 9, 2012
Last verified: November 2012

RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide and bicalutamide, may lessen the amount of androgens made by the body. Implant radiation therapy kills tumor cells by placing material such as radioactive iodine directly into or near a tumor. Giving leuprolide and bicalutamide together with implant radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying the side effects of giving leuprolide and bicalutamide together with implant radiation therapy and to see how well it works in treating patients with locally recurrent prostate cancer after external-beam radiation therapy.

Condition Intervention Phase
Prostate Cancer Drug: bicalutamide Drug: leuprolide acetate Procedure: adjuvant therapy Procedure: neoadjuvant therapy Procedure: quality-of-life assessment Radiation: brachytherapy Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase II Interstitial Brachytherapy Combined With Androgen Deprivation Therapy for Locally Recurrent Prostate Cancer After Prior External Beam Irradiation

Resource links provided by NLM:

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • Feasibility
  • Patient tolerance
  • Toxicities
  • Tumor response

Estimated Enrollment: 50
Study Start Date: April 2000
Study Completion Date: October 2005
Primary Completion Date: October 2005 (Final data collection date for primary outcome measure)
Detailed Description:


  • Determine the feasibility and patient tolerance of interstitial brachytherapy combined with androgen-deprivation therapy for patients with locally recurrent prostate cancer after prior external-beam irradiation.
  • Determine the toxicity of interstitial brachytherapy combined with androgen-deprivation therapy in these patients.
  • Determine the tumor response to interstitial brachytherapy combined with androgen-deprivation therapy in these patients.

OUTLINE: Patients receive neoadjuvant therapy comprising leuprolide acetate intramuscularly for 3 months and oral bicalutamide once daily for 30 days, beginning on the first day of leuprolide acetate administration. Patients then undergo interstitial brachytherapy implantation with I-125. Following brachytherapy, patients receive adjuvant leuprolide acetate every 3 months for an additional 6 months.

Quality of life is assessed at baseline and at every treatment and follow-up visit.

After completion of study therapy, patients are followed every 3 months for 2 years, every to 4-6 months for 3 years, and then annually thereafter.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Biopsy-proven adenocarcinoma of the prostate

    • Locally recurrent disease, defined by digital rectal examination and/or rising prostate-specific antigen (PSA)
  • No evidence of nodal or distant metastasis (i.e., N0, M0) on physical examination, bone scan, or CT scan of the pelvis
  • Clinical stage T1c-T3a disease at the time of recurrence
  • PSA < 10 ng/mL
  • Prostate volume by transrectal ultrasonography < 60 cc
  • Received prior external beam radiotherapy


  • ECOG performance status 0-2
  • WBC ≥ 3,000/μL
  • Platelet count ≥ 90,000/μL
  • Hemoglobin ≥ 10 g/dL
  • Alkaline phosphatase < 2 times normal
  • AST < 2 times normal
  • Normal prothrombin time and partial thromboplastin time
  • No significant obstructive urinary symptoms (AUA score ≤ 16)
  • No contraindication for general anesthesia


  • See Disease Characteristics
  • No prior transurethral resection of the prostate
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00684905

United States, Arizona
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259
Sponsors and Collaborators
Mayo Clinic
National Cancer Institute (NCI)
Study Chair: William W. Wong, MD Mayo Clinic
  More Information

Responsible Party: William Wailing Wong, M.D., Mayo Clinic Cancer Center Identifier: NCT00684905     History of Changes
Obsolete Identifiers: NCT00956995
Other Study ID Numbers: 07-00
P30CA015083 ( US NIH Grant/Contract Award Number )
7-00 ( Other Identifier: Mayo Clinic Cancer Center )
7-00 ( Other Identifier: Mayo Clinic IRB )
Study First Received: May 14, 2008
Last Updated: November 9, 2012

Keywords provided by Mayo Clinic:
adenocarcinoma of the prostate
recurrent prostate cancer
stage I prostate cancer
stage II prostate cancer
stage III prostate cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Androgen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on June 23, 2017